Wegovy low dose: what 0.25 mg, 0.5 mg, and 1.7 mg are for

What people mean by Wegovy low dose

Search traffic for 'Wegovy low dose' usually points at the first pens in the box: 0.25 mg and 0.5 mg once weekly. The label uses those strengths as a four-week-per-step climb toward maintenance. Some people also call 1.7 mg 'low' because it is below the recommended 2.4 mg weekly maintenance. Those are different ideas. One is initiation. The other is an approved maintenance choice.

This article is educational, not medical advice. Beema Health does not dispense Wegovy. A prescription is required. Completing an online visit does not guarantee a prescription. Individual results vary.

0.25 mg and 0.5 mg: initiation, not the study's target dose

Table 1 of the Wegovy injection label starts every approved injection indication at 0.25 mg weekly for weeks 1-4, then 0.5 mg for weeks 5-8, then 1 mg, then 1.7 mg. If a patient does not tolerate a step, the prescriber may delay escalation for four weeks. That delay is labeled flexibility. It is not an invitation to stay on 0.25 mg as a lifestyle dose.

STEP 1, which supports much of the public conversation about 'how much weight Wegovy loses,' evaluated 2.4 mg after escalation, not chronic 0.25 mg. Using a starter pen because a 2.4 mg pen is hard to obtain is a supply and access problem to discuss with a clinician and pharmacy, not a new indication.

When 1.7 mg is a labeled maintenance option

For adult weight reduction, maintenance is 1.7 mg or 2.4 mg weekly, with 2.4 mg recommended. For adult cardiovascular risk reduction, the same two options appear. Pediatric patients 12 years and older also have 1.7 mg or 2.4 mg maintenance choices. For noncirrhotic MASH with moderate to advanced fibrosis, the recommended maintenance is 2.4 mg, with a decrease to 1.7 mg if 2.4 mg is not tolerated, and possible re-escalation.

A clinician may choose 1.7 mg when gastrointestinal effects, other adverse reactions, or patient preference make 2.4 mg a poor fit. That is still a labeled strength, supplied as its own pen, not a homemade fraction of a 2.4 mg dose.

How 'low' compares with 2.4 mg and 7.2 mg

The usual recommended injection maintenance remains 2.4 mg weekly for most adult weight and cardiovascular uses. The current label also allows increasing to a maximum of 7.2 mg weekly in adults who have tolerated 2.4 mg for at least four weeks when additional weight reduction is clinically indicated. That higher option makes 'low dose' even easier to misunderstand. Low is relative to the recommended maintenance, not a separate product line.

Tablet Wegovy uses milligram numbers that look larger (1.5 mg to 25 mg daily) because oral bioavailability is much lower. Do not compare a 0.25 mg injection with a 1.5 mg tablet as if they were the same exposure.

Delayed titration versus unofficial microdosing

Clinicians routinely pause an increase when nausea, vomiting, or constipation is intense. That is conservative use of the labeled schedule. Unofficial 'microdosing' may involve counting clicks, diluting, or staying on starter doses for months without a monitoring plan. Those practices can under-treat the condition the medicine was prescribed for, leave leftover product that is easy to misuse, and skip safety follow-up.

If side effects are the reason someone wants a lower dose, the safer path is to tell the prescriber, who can delay a step, treat constipation or dehydration, or reconsider whether Wegovy is appropriate at all. Stopping without a plan is covered in the stopping GLP-1 article.

Prescription-only and Beema Health

Every Wegovy strength is prescription-only. There is no legitimate cart checkout for a 'low-dose Wegovy' kit online without a licensed clinician. Beema Health does not offer Wegovy. If you are exploring telehealth medical weight loss, Beema's program overview explains how intake and provider review work. That is not a substitute-for-Wegovy claim.

Frequently asked questions

Sources

1. [1] Wegovy (semaglutide) U.S. Prescribing Information, Novo Nordisk
2. [2] DailyMed: Wegovy (semaglutide) injection and tablets
3. [3] Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021.
4. [4] Rubino D, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021.